Cerveau Technologies and Ionis Pharmaceuticals set up a partnership

| By | Drug Development, Pharmaceutical Deal

Cerveau Technologies announced a research collaboration agreement with Ionis Pharmaceuticals for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.

NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The collaboration is focused on using [F-18]MK-6240 as a biomarker in Ionis neurodegenerative disease research studies. The parties will collaborate to evaluate the effect of therapies on the progression of neurodegenerative diseases in humans such as Alzheimer disease.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.

SOURCE: businesswire
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.